Friday , November 27 2015

From the Editor

November, 2015

  • 24 November


    When you do the math, 95% of all diabetes patients have type 2. This does not mean that we should ignore type 1 patients when looking at psychological problems; in fact, most of the information on these problems deals with type 1 patients. These problems can include development of diabetes, ...

    Read More »

Latest Articles

November, 2015

Test Your Knowledge

Question #808

A 75-year-old man presents to your office with complaints of occasional mild hypoglycemia. His current antihyperglycemic regimen includes metformin and nateglinide. You would like to modify his treatment regimen to minimize his risk of hypoglycemia. Which one of the following 2-drug combinations would NOT be a suitable substitution?

Select one answer:


Answer B. Metformin + glipizide

In this case, the sulfonylureas (glipizide) and meglintinides (nateglinide) can lead to hypoglycemia (meglinitides less so than sulfonylureas). The thiazolidinediones (pioglitazone), DPP-4 inhibitors (vildaglipitin), GLP-1 agonists (exenatide) and metformin have low hypoglycemic potential as a side effect. The thiazolidinediones (pioglitazone), DPP-4 inhibitors (vildaglipitin) and GLP-1 agonists (exenatide) can be used in various combinations with metformin to provide glycemic control when the goal is to minimize hypoglycemia.


Inzucchi S, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6):1364-1379.



More Articles

November, 2015